




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/62, A01K 67/027, C12N 15/00, C07K 14/705, 14/815, 14/81, C12N 9/64	A1	(11) International Publication Number: WO 98/42850 (43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/GB98/00850 (22) International Filing Date: 26 March 1998 (26.03.98) (30) Priority Data: 9706327.5 26 March 1997 (26.03.97) GB 9720248.5 23 September 1997 (23.09.97) GB (71) Applicant (for all designated States except US): RPMS TECHNOLOGY LIMITED [GB/GB]; Commonwealth Building, Du Cane Road, London W12 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): RIESBECK, Kristian [SE/SE]; Ostra Promenaden 11A, S-211 28 Malmo (SE). DORLING, Anthony [GB/GB]; 28 Coldfall Avenue, Muswell Hill, London N10 1HS (GB). GEORGE, Andrew, John, Timothy [GB/GB]; 2 Glendale House, Cardigan Road, Richmond, Surrey TW10 6BW (GB). LECHLER, Robert, Ian [GB/GB]; 78 Woodstock Road, Chiswick, London W4 1EQ (GB). (74) Agent: HOWARD, Paul, Nicholas; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: ANTICOAGULANT FUSION PROTEIN ANCHORED TO CELL MEMBRANE**(57) Abstract**

The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANTICOAGULANT FUSION PROTEIN ANCHORED TO CELL MEMBRANE

FIELD OF THE INVENTION

This invention relates to the inhibition of blood coagulation, especially during organ rejection.

BACKGROUND TO THE INVENTION

5 The surgical technique of organ transplantation has now been successfully practised for several decades and, because of its success, the procedure has become widespread and, arguably, routine. However, the supply of suitable transplant organs is not able to match ever-rising demands.

Because of the shortage of suitable human (*ie.* allogeneic) organs, the possibility of using animal (*ie.* xenogeneic) organs in human transplant operations ("xenografting" or "xenotransplantation")
10 has been receiving increased attention in recent years (*eg.* *Nature* 1997; 385: 285). Porcine donor organs are thought to be suitable candidates because pigs are anatomically and physiologically similar to humans and are in abundant supply.

Xenografting is currently hindered, however, by the severe and well-documented problems of rejection. This process can be divided into distinct stages, the first of which occurs within
15 minutes of transplantation. This is known as the hyperacute response and is caused by existing antibodies in the recipient which recognise and react with foreign antigens on the endothelial cells (ECs) of the xenograft. This recognition triggers the complement cascade which in turn leads to lysis and death of ECs of the transplant.

This initial hyperacute rejection is then reinforced by the delayed vascular response (also known
20 as acute vascular rejection or delayed xenograft rejection). The lysis and death of ECs during the hyperacute response is accompanied by oedema and the exposure of adventitial cells, which constitutively express tissue factor (TF) on their surface. Tissue factor is thought to be pivotal in the initiation of the *in vivo* coagulation cascade, and its exposure to plasma triggers the clotting reactions. Thrombin and TNF- α become localised around the damaged tissue and this induces
25 further synthesis and expression of TF by ECs.

The environment around resting ECs does not favour coagulation. Several natural coagulation inhibitors are associated with the extracellular proteoglycans of ECs, such as tissue factor pathway inhibitor, antithrombin III, and thrombomodulin. The recognition of the foreign tissue by xenoreactive natural antibodies (XNAs), however, causes the loss of these molecules.

Together with the exposure and induction of tissue factor, the anticoagulant environment around ECs thus becomes pro-coagulant.

The vascularised regions of the xenograft thus become sites of blood clots, a characteristic of damaged tissue. Blood flow is impaired and the transplanted organ becomes ischaemic. A fuller
5 account of delayed vascular rejection can be found in Bach *et al.* (1996).

The use of xenogeneic organs in transplants is therefore hindered by an initial hyperacute rejection followed by a prolonged vascular rejection, possibly followed by T-cell mediated rejection. Inhibition of the mechanisms responsible for these rejections could facilitate the use of xenografts.

10 The simple administration of suitable inhibitors, however, is not a particularly suitable approach. Completely inhibiting complement in a recipient animal is tantamount to immunosuppression, leaving the subject prone to opportunistic infections. Similarly, inhibiting the coagulation cascade in a recipient will leave the animal susceptible to uncontrolled post-operative bleeding. Therefore the inhibitors should desirably be localised in the recipient to the site of the xenograft.

15 The prevention of hyperacute rejection is the subject of European patent 0495852 (Imutran). To make tissues more suitable for xenografting this patent teaches that they should be associated with homologous complement restriction factors, which prevent the complete activation of complement in the xenogeneic organ recipient.

This approach has been developed and applied in order to produce transgenic animals with
20 organs designed to survive hyperacute rejection (Squinto, 1996). Transgenic mice expressing human CD59, a complement regulator, on cardiac ECs have been produced (Diamond, 1995). The human CD59 retained biological activity and complement was inhibited when transgenic hearts were perfused with human plasma.

Transgenic pigs expressing human DAF and/or CD59 have been reported (McCurry, 1996).
25 Cardiac rejection took twice as long to occur with the transgenic xenografts than with controls.

Inhibiting delayed vascular rejection has not received the same attention, although inhibitors of the coagulation cascade are well known in the art and many have been well characterised.

For instance, tissue factor pathway inhibitor (TFPI) is known to inhibit the function of the active complex which is normally formed between tissue factor, factor VIIa, and factor Xa. TFPI is a

276 residue soluble polypeptide whose positively charged C-terminus binds to heparin sulphate in the proteoglycan layer of ECs. It has been notionally divided into three "Kunitz" domains: Kunitz domain I is responsible for binding tissue factor and factor VIIa; domain II binds factor Xa; but the functions of domain III are less clear (Hamamoto, 1993).

- 5 Tick anticoagulant peptide (TAP) is a specific and potent inhibitor of factor Xa. This 60 amino acid polypeptide has been purified from the soft tick *Ornithodoros moubata*.

Many snake venoms also contain anticoagulant polypeptides. For instance, a 231 amino acid protein C activator has been purified from the venom of the snake *Agkistrodon contortrix contortrix* (McMullen, 1989; Kisiel, 1987).

- 10 Hirudin is the anticoagulant protein utilised by the leech *Hirudo medicinalis* when extracting blood from its victim. It is highly potent and binds to thrombin at a 1:1 ratio with a dissociation constant in the femtomolar range. The active site of thrombin is masked in the stable complex and so the hirudin prevents fibrinogen breakdown, thus inhibiting clot formation.

- One possible approach for localising anticoagulants to the site of rejection is to link hirudin to
15 antibodies against E-selectin, which is expressed on the surface of ECs during cell activation. This approach has been shown to be effective in inhibiting clot formation *in vitro* (Kiely, 1995). Other possible strategies were recently reviewed by Bach *et al.* (1996).

- P-selectin (also known as CD62) is also expressed on the surface of ECs during cell activation. During synthesis it is targeted to secretory storage granules in platelets and endothelial cells by
20 sequences residing in its cytoplasmic domain (Disdier, 1992). In response to cell agonists, such as thrombin, the granules are rapidly redistributed and P-selectin is expressed on the cell surface (Green, 1994).

- It is an object of the present invention to provide membrane-bound anticoagulant proteins. These proteins are suitable for inhibiting the clotting cascade at the surface of ECs, thus inhibiting
25 *in vivo* mechanisms responsible for organ rejection.

It is a further object to provide regulated expression of such molecules on the surface of ECs such that coagulation inhibition occurs locally during conditions of organ rejection. The rejection might be xenogeneic or allogeneic.

- It is yet a further object of the invention to provide biological tissue suitable for transplantation,
30 particularly for xenotransplantation.

DESCRIPTION OF THE INVENTION

According to a first aspect of the present invention there is provided a protein comprising a region with anticoagulant activity and a region which can anchor said protein to a cell membrane. Preferably this is a chimeric protein, that is to say the anchor region and anticoagulant region are
5 derived from different proteins.

The anticoagulant region can comprise the sequence of any anticoagulant polypeptide. Examples of such anticoagulant polypeptides include heparin, TAPs, antithrombin, hirudins, and TFPIs, along with their functional derivatives, such as fragments and derivatives which retain anticoagulant activity. Anticoagulant derivatives of thrombin, normally a procoagulant, have also
10 been reported (Dang, 1997).

Preferably the anticoagulant region comprises the sequence of a hirudin. Hirudins include hirudin, hirudin derivatives, analogs ("hirulogs"), and variants (*eg.* hirudisins). For instance, it has been reported that sulphation at Tyr-64 increases the anticoagulant activity of hirudin, and that hirudisin-2 is a more potent inhibitor of thrombin activity than hirudin itself (*eg.* Knapp,
15 1992; Skern, 1990).

As an alternative, the anticoagulant region might comprise the sequence of a tissue factor pathway inhibitor (TFPI). TFPIs include TFPI itself and derivatives or analogs thereof which retain inhibitory activity. Preferably the TFPI sequence comprises Kunitz domains I and II of TFPI itself.

20 As a further alternative, the anticoagulant region might comprise the sequence of a tick anticoagulant peptide (TAP). TAPs include TAP itself and derivatives or analogs thereof which retain inhibitory activity. For instance, the potency of FXa inhibition by TAP has been enhanced by site-directed mutagenesis (*eg.* Mao, 1995).

Further alternative anticoagulant regions could, for instance, comprise the sequence of a protein
25 C activator, such as those isolated from snake venom (*eg.* McMullen, 1989; Kisiel, 1987), or the sequence of anticoagulants isolated from snake venoms which act other than via protein C activation, or their derivatives or analogs which retain anticoagulant activity.

The anchor region can be any entity which can attach the protein to a cell membrane. Suitable examples include transmembrane sequences from membrane proteins and GPI anchors.
30 Preferably the anchor region is a sequence capable of attaching the protein to a lipid bilayer, such

as the transmembrane regions of the HLA class I or CD4 proteins. It may also be desirable for the protein to comprise the cytoplasmic domain which is usually associated with said transmembrane regions, such as the CD4 cytoplasmic domain, and/or the extracellular domains immediately juxtaposed with the cell membrane, such as CD4 domains 3 and 4. Alternatively the anchor region might be a sequence conferring on the protein the ability to associate extracellularly with a membrane protein without the protein itself being inserted into the cell membrane.

According to a second aspect of the invention, there is provided a protein according to the first aspect further comprising a targeting sequence which prevents the protein from being constitutively expressed at the cell surface.

Preferably the targeting sequence is a polypeptide sequence which can target a nascent polypeptide to a secretory granule, and more preferably the secretory granule is one which does not fuse with the cell's plasma membrane until the cell is suitably stimulated. For example, Weibel-Palade bodies do not fuse with the plasma membrane until the endothelial cell surface is stimulated by a secretagogue, such as thrombin or fibrin (Wagner, 1993). Preferably the secretory granule fuses with the plasma membrane during EC activation which occurs during organ rejection.

Thus the targeting sequence is preferably one which targets a nascent polypeptide to a Weibel-Palade body, such as the relevant sequence from P-selectin. Most preferably the protein according to the second aspect of the invention comprises an anticoagulant sequence and the transmembrane and cytoplasmic domains of P-selectin. The domains from P-selectin thus provide both the anchor sequence and the targeting sequence.

According to a third aspect of the invention, there is provided a polynucleotide encoding a protein according to the present invention. Preferably the polynucleotide is DNA.

Preferably the polynucleotide comprises sequences suitable for the regulation of expression of protein according to the invention. This expression can preferably be controlled, such as cell-specific control, inducible control, or temporal control. For instance, expression might be specific for ECs, or might be regulated in response to cell activation.

According to a fourth aspect of the invention, there is provided a vector comprising a polynucleotide according to the third aspect.

The term "vector" signifies a molecule which is capable of transferring a polynucleotide to a host cell. Preferably the vector is a DNA vector and, more preferably, is capable of expressing RNA encoding a protein according to the invention. Numerous suitable vectors are known in the art.

Preferably the vector is suitable for the production of a transgenic animal. Vectors suitable for the generation of transgenic pigs, for example, are described in Heckl-Östreicher (1995), McCurry (1996), White (1995), Yannoutsos (1995), and Langford (1996). Minigene vectors suitable for the generation of transgenic mice are described in Diamond (1995).

According to a fifth aspect of the invention, there is provided a delivery system comprising a molecule of the first, second, third, or fourth aspects and means to deliver said molecule to a target cell.

Certain vectors according to the fourth aspect may also function as suitable delivery systems. Likewise, certain delivery systems according to this fifth aspect may also inherently be vectors, but this is not always the case. For instance, a viral vector can also function as a delivery system, whereas a liposomal delivery system is not a vector.

The delivery system may be viral or non-viral. Non-viral systems, such as liposomes, avoid some of the difficulties associated with virus-based systems, such as the expense of scaled production, poor persistence of expression, and concerns about safety. Preferably the delivery system is suitable for use in gene therapy. Numerous appropriate delivery systems are known in the art.

Preferably, the delivery system will be targeted so that molecules according to the present invention are taken up by cells suitable for transplantation, or cells which have been transplanted. More preferably the delivery system will be specific for these cells. For example, the delivery system may be targeted to a specific organ, such as the heart or the kidney, or to a specific cell type, such as endothelial cells.

To achieve this the delivery system may, for example, be a receptor-mediated delivery system, being targeted to receptors found on target cells. For example, the delivery system may be targeted to receptors found on heart cells, preferably to receptors found exclusively on heart cells, or it may be targeted to receptors found on endothelial cells, preferably to receptors found exclusively on endothelial cells, or to receptors found on activated endothelial cells, such as E-selectin or P-selectin.

The delivery system is preferably suitable for the generation of transgenic animals. For example,

the delivery system may be targeted to a gamete, a zygote, or an embryonic stem cell.

According to a sixth aspect of the invention, there is provided a method of transfecting a cell with a vector according to the invention. This may involve the use of a delivery system according to the invention.

- 5 The cell type is not restricted and may be prokaryotic or eukaryotic. Transfection can occur *in vivo* or *ex vivo*.

Where the cell is for use in transplantation, the cell is preferably eukaryotic, more preferably an endothelial cell. The stable transfection of porcine endothelial cells, for example, is described in Heckl-Östreicher (1995).

- 10 Preferably, the cell is suitable for the generation of a transgenic animal. More preferably, the cell is a gamete, a zygote, or an embryonic stem cell. The transfection of murine ova by microinjection to generate transgenic mice, for example, is described in Diamond (1995), and the microinjection of porcine zygotes, for instance, to generate transgenic pigs is described in Yannoutsos (1995), Langford (1996), and White (1995).

- 15 According to a seventh aspect of the invention, there is provided a cell transfected according to the sixth aspect.

To increase the efficacy of inhibition of the coagulation cascade, the cell is preferably able to express two or more different proteins according to the invention, each of which inhibits the coagulation cascade at a different stage. For example, the anticoagulant region in one protein
20 might comprise a TFPI, whilst in the other it comprises a hirudin.

According to an eighth aspect of the invention, there is provided biological tissue comprising a cell according to the invention. The term "biological tissue" as used herein includes collections of cells, tissues, and organs. Accordingly the definition includes, for example, fibroblasts, a cornea, nervous tissue, a heart, a liver, or a kidney.

- 25 According to a ninth aspect of the invention, there is provided an animal comprising a cell and/or biological tissue according to the invention. Preferably the animal is suitable for the production of organs for transplantation into humans. Preferably the animal is a mammal, and more preferably it is a transgenic pig or a transgenic sheep.

The animal might be treated whilst alive such that it comprises transgenic biological tissue (*ie.*

treated by gene therapy). Preferably, a live animal is transfected with a vector according to the invention in order to produce a transgenic animal. For example, a vector according to the invention could be specifically delivered to endothelial cells in a pig to produce transgenic organs suitable for xenotransplantation.

- 5 Alternatively, the animal might be born as a transgenic animal. Various suitable approaches for generating such transgenic animals are known in the art (*eg.* Bradley & Liu, 1996; Clarke, 1996; Wheeler, 1994). For example, direct manipulation of the zygote or early embryo, by microinjection of DNA for instance, is well known, as is the *in vitro* manipulation of pluripotent cells such as embryonic stem cells. Retroviral infection of early embryos has proved successful
10 in a range of species, and adenoviral infection of zona-free eggs has been reported. Transgenesis and cloning of sheep by nuclear transfer has also been described (*eg.* WO97/07668).

According to a tenth aspect of the invention, there is provided a method of rendering biological tissue suitable for transplantation, comprising expressing one or more proteins according to the present invention in said biological tissue, preferably in its endothelial cells. The biological tissue
15 may be so rendered either *in vivo* or *ex vivo*. For example, an animal organ may be *in vivo* transfected with a vector according to the invention, or an organ could be transfected *ex vivo* before transplantation or *in vivo* after transplantation.

According to an eleventh aspect of the invention, there is provided a method of transplantation comprising transplanting biological tissue according to the invention from a donor animal into a
20 recipient animal. Preferably the method is for xenotransplantation and the donor biological tissue is xenogeneic with respect to the recipient animal.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows maps of hirudin-CD4 chimeric proteins and constructs according to the invention. (A) HLA-hirudin-CD4 constructs with glycine linkers. (B) HLA-hirudin-CD4
25 construct with human P-selectin C-terminal, with the specific targeting sequence underlined. Transmembrane (TM), stop transfer (ST), and cytoplasmic (C) regions of CD4 are indicated.

Figure 2 shows FACS profiles for HLA-hirudin-CD4 constructs expressed in DAP.3 fibroblasts.

Figure 3 shows FACS profiles for HLA-hirudin-CD4-P-selectin cDNA constructs expressed in CHO-K1.

Figure 4 shows that hirudin-CD4 expressing fibroblasts bind thrombin.

Figure 5 shows the specificity of thrombin binding to cells expressing hirudin-CD4.

Figure 6 shows thrombin binding to CHO-K1 cells transfected with HLA-hirudin constructs.

Figure 7 shows that inactivation of thrombin abolishes thrombin binding to hirudin-CD4 at the cell surface. Cells expressing hirudin-G2-CD4 were incubated with thrombin or inactivated thrombin and stained for thrombin binding with anti-prothrombin or anti-thrombin-hirudin antibodies.

Figure 8 shows maps of TFPI-CD4 chimeric proteins and constructs according to the invention.

Figure 9 shows flow cytometry profiles of DAP.3 cells expressing TFPI tethered to the cell surface.

Figure 10 shows specific FXa binding to cell surface bound TFPI₁₋₂₇₆-CD4 and TFPI₁₋₁₈₃-CD4.

Figure 11 shows the blocking of FXa binding by a polyclonal anti-TFPI immunoglobulin fraction.

Figure 12 shows the blocking of FXa binding by monoclonal antibodies directed against Kunitz domains I and II.

Figure 13 shows the inhibition of FXa by cells expressing TFPI₁₋₂₇₆-CD4 and TFPI₁₋₁₈₃-CD4. The mean time for a FXa-specific chromogenic substrate to reach OD₄₀₅=0.1 is shown for transfected DAP.3 cells incubated with FXa. Values for control cells were subtracted and error bars indicate standard deviations.

Figure 14 shows that an active TF₁₋₂₁₉/FVIIa complex is required for maximal binding to TFPI-CD4 chimeric proteins.

Figure 15 shows the specificity of thrombin binding to immortalised porcine endothelial cells (IPEC) expressing hirudin-CD4, and also shows the effect of cell-surface hirudin-CD4 expression on clotting times.

Figure 16 shows the distribution of ACTH and hirudin in D16/16 cells, as revealed by fluorescence.

Figure 17 shows the change in cellular distribution of hirudin-CD4-P-selectin after PMA

stimulation

Figure 18 shows that TFPI-CD4 expressed on IPEC retains its binding properties.

Figure 19 shows the competitive binding of porcine and human tissue factors.

Figure 20 shows that TFPI-CD4 prolongs clotting times when expressed on IPEC surface.

5 **Figure 21** shows the anti-coagulant effect of co-expression of TFPI-CD4 and hirudin-CD4.

DESCRIPTION OF EMBODIMENTS

1. Hirudin fused with HLA class I signal peptide and linked to domains 3 and 4 of human CD4 is tethered to the cell membrane

10 To express heterologous hirudin constructs in mammalian cells, the cDNA for the membrane-targeting signal peptide leader sequence from human HLA class I A2.1, amino acids -1 to -24 (Holmes, 1987), was fused to hirudin variant 1 (Dodt, 1984) using PCR with overlapping extension (Figure 1).

The HLA A2.1 leader sequence was amplified using primers:

5'-cagtgtcgacggatccatggccgcatggcgccccga-3' [hla-1] <SEQ ID 1>

15 (introducing *SalI* and *BamHI* restriction sites) and:

5'-gtcagtgtaaacaaccgcccaggtctgggtcagg-3' <SEQ ID 2>

The hirudin sequence was amplified using primers:

5'-accagacctgggcggtgtttactgactgcacc-3' and <SEQ ID 3>

5'-gacgctgcagaattcttcaggtattctccgggatt-3' [hir-3] <SEQ ID 4>

20 (introducing distal *EcoRI* and *PstI* sites).

The resulting PCR products (108 and 228 bp) were purified by agarose gel electrophoresis and then used in a third PCR using flanking primers hla-1 and hir-3. The resulting PCR product (300 bp) was digested with *SalI* and *BamHI* and subcloned into pBluescript SK(+) (Stratagene).

25 An anchor consisting of a cDNA encoding for CD4 domains 3 and 4 (Maddon, 1985) in conjunction with the stop transfer sequence (ST), transmembrane and cytoplasmic domains of

CD4 (CD4₁₆₆₋₄₃₅) was added to the HLA-hirudin cassette.

To ensure that hirudin stayed mobile and active when linked by its C-terminal to the CD4 anchor, however, 3 different glycine linker lengths were made (designated G1 to G3 – Fig. 1A):

- for glycine linker 1 (G1; GGSGG), the oligonucleotide pair consisted of
5'-aattaggagggttctggaggctgca-3' <SEQ ID 5> (containing a mutated *Eco*RI recognition sequence and a *Pst*I site) and 5'-gcctccagaacctcct-3' <SEQ ID 6>;
- glycine linkers 2 (G2) and 3 (G3) consisted of the core sequence (GGSGG) repeated two or three times, respectively.

These linkers were introduced into the 3' end of the HLA-hirudin fragment.

- 10 The glycine linker oligonucleotides were annealed and each ligated into the *Eco*RI/*Pst*I site of plasmids containing the HLA-hirudin cassette, prior to the insertion of the CD4 anchor.

CD4₁₆₆₋₄₃₅ was amplified using primers:

5'-tgtctgcaggaaccagaagaaggtggaattca-3' <SEQ ID 7>

(introducing *Pst*I and *Eco*RI sites) and:

15 5'-gtgggatccgcctggcctcgtgcctcaa-3' <SEQ ID 8>

(containing a distal *Bam*HI).

The resulting PCR product was cloned into pBluescript and sequenced. In CD4₁₆₆₋₄₃₅, V³²⁸ was found to be mutated to A³²⁸. The *Pst*I/*Bam*HI CD4 fragment was subcloned into HLA-hirudin -G1, -G2, & -G3 plasmids, and these constructs were verified by DNA sequence analysis.

- 20 Each of the three cDNA constructs were subcloned into the *Bam*HI site of the mammalian expression vector pH β Actpr-1gpt (Gunning, 1987), containing the human β -actin enhancer and promoter region in conjunction with an SV40 enhancer element driving the gpt resistance gene, allowing the selection of clones in the presence of mycophenolic acid (Figures 1C & 1D). The orientation of the final constructs was verified by restriction endonuclease mapping.

- 25 Vectors containing the individual HLA-hirudin-G1/2/3-CD4 constructs were transfected into mouse fibroblast cell line DAP.3 (Marguelies, 1983) with calcium-phosphate according to standard protocols. After 18 hours growth in DMEM medium (Gibco) supplemented with 5%

fetal calf serum, ampicillin, streptomycin, and glutamine, cells were glycerol treated for 30 seconds. Cells were then washed twice with phosphate buffered saline (PBS), and new medium including xanthine, hypoxanthine, and mycophenolic acid to a final concentration 12µg/ml, was added.

- 5 For a negative control, DAP.3 cells transfected with a human class II construct expressing HLA-DR (cell line 531) (Lechler, 1988) grown in identical mycophenolic acid-containing culture medium.

Surviving clones were tested for hirudin and CD4 expression by FACS using murine monoclonal antibodies 4158-81-7 (Schlaeppli, 1991) and OKT-4 (Reinherz, 1979) respectively. 10⁵ cells were
10 stained with the murine antibodies for 30 minutes on ice and a FITC-conjugated sheep anti-mouse polyclonal antibody was added as a secondary layer.

As shown in Figure 2, these hirudin-CD4 constructs were well expressed at the cell surface of DAP.3. No significant difference in expression levels was detected between hirudin-CD4 with the three different glycine linker lengths.

- 15 Therefore anticoagulant polypeptides can be stably expressed on the cell surface.

2. Hirudin-CD4 with a targeting sequence from the C-terminal of P-selectin is expressed at the cell surface of CHO-K1

In addition to the HLA-hirudin-G1/2/3-CD4 constructs, two more constructs were synthesised with targeting sequences derived from human P-selectin (Figure 1B). The transmembrane region
20 from CD4 was used for these constructs, while the stop transfer sequence and C-terminal were replaced with the corresponding sequences from P-selectin (Johnston, 1989).

To fuse CD4 domains 3 and 4 plus the transmembrane region (CD4₁₆₆₋₃₉₅) with the stop transfer sequence and cytoplasmic regions 1 and 2 of human P-selectin (P-sel₇₅₄₋₇₈₉) (McEver 1989), PCR
25 with overlapping extension was performed. For amplification of the CD4 part of the molecule, primers:

5'-tgtctgcaggaaccagaagaaggtggaattca-3' [CD4-5] <SEQ ID 7>

(introducing *Pst*I and *Eco*RI restriction sites) and:

5'-gtctgaaacgctttctgaagaagatgcctagcccaatgaaaagcaggaggccg-3' <SEQ ID 9>

were used. In parallel, to amplify the C-terminal region of P-selectin, primers:

5'-tgggctagcatcttcttcagaaagcgttcagacaaaaaga-3' and <SEQ ID 10>

5'-gaccaggatccggacaggtctctta-3' [P-selN3] <SEQ ID 11>

(introducing a distal *Bam*HI site) were used.

- 5 After purification of resulting PCR products from agarose gels, a third PCR was run using the flanking primers CD4-5 and P-selN3. The resulting PCR product (832 bp) was digested with *Pst*I and *Bam*HI, subcloned into pBluescript, and sequenced. Thereafter, the CD4-P-sel fragment (CD4₁₆₆₋₃₉₅-P-sel₇₅₄₋₇₈₉) was excised with *Pst*II/*Bam*HI and subcloned into plasmids containing HLA-hirudin-G1 or -G2.
- 10 The final HLA-hirudin-G1/G2-CD4-P-selectin constructs were subcloned into the *Bam*HI site of pH β Actpr-1gpt and transfected into CHO-K1 cells (ATCC CCL61), grown in RPMI 1640 medium (Gibco) supplemented with 5% fetal calf serum, ampicillin, streptomycin, and glutamine.

- 15 Transfection was by electroporation according to standard protocols. Briefly, 5x10⁶ cells were resuspended in 350 μ l serum-free medium and transferred to a 1 ml electroporation cuvette with a 0.4 cm space between electrodes (Bio-Rad). After addition of 10 μ g plasmid DNA in 150 μ l, samples were gently shaken and kept on ice. Cells were subjected to electroporation at infinite resistance, 960 μ F and 350 V in a Gene Pulser apparatus (Bio-Rad). The day after electroporation, cells were washed twice with PBS and new medium including mycophenolic acid, xanthine, and hypoxanthine was added.
- 20

- Recently it was shown that when CHO-K1 cells were transfected with P-selectin cDNA, P-selectin protein was not accumulated intracellularly, but was expressed at the cell surface (Disdier, 1992). In the CHO-K1 transfectants produced above, both hirudin-G1-CD4-P-selectin and hirudin-G2-CD4-P-selectin were expressed at the surface as judged by staining with OKT-4 and 4158-81-7 monoclonals (Figure 3). The negative control used was a CHO-K1 cell line expressing TFPI fused to CD4 domains 3 and 4 (TFPI-CD4₁₆₆₋₄₃₅), grown in the same mycophenolic acid-containing medium.
- 25

As a positive control, CHO-K1 cells were transfected with full length human P-selectin (Johnston, 1989), which was subcloned as a 3142bp *Sa*I fragment into pH β Actpr-1neo

containing an SV40-driven neomycin (G418) resistance gene. These cells were treated with 400 µg/ml G418 and after 2 weeks individual clones were picked with cotton swabs and transferred to 12-well plates. Surviving clones were analysed for hirudin and CD4 expression using 4158-81-7 at 10 µg/ml and an undiluted OKT-4 hybridoma supernatant.

- 5 Human P-selectin was detected by anti-CD62 mAb (Becton Dickinson), according to the manufacturer's recommendations. A similar FACS profile as with hirudin-CD4-P-selectin was observed for these CD62-labelled cells (Figure 3E), confirming that CHO-K1 cells express P-selectin at the plasma membrane.

Thus, chimeric proteins comprising the P-selectin targeting sequence remain functional when
10 expressed at the cell surface.

3. Hirudin anchored to the cell surface binds thrombin as detected with specific antibodies

To test whether hirudin tethered in this way to the cell surface retains its thrombin binding activity, the following binding assay was used.

- 15 Stably transfected cells were grown in T75 culture flasks for 36 hours before each experiment. DAP.3 cells were detached using a cell scraper, whilst CHO-K1 cells were detached from the plastic by treatment with PBS, 5 mM EDTA for 10 minutes at 37°C. After 4 washes with PBS containing 0.1% BSA (w/v), 2.5×10^5 cells in 150 µl were incubated for 1 hour at 37°C with increasing concentrations of thrombin. The cells were washed four times with PBS containing
20 0.1% BSA and further incubated for 30 minutes on ice with rabbit anti-human prothrombin immunoglobulins (10 µg/ml in 100 µl) (Dakopatts). After two further washes, cells were incubated for 30 minutes with FITC-conjugated swine anti-rabbit immunoglobulins (Dakopatts). Finally, transfectants were washed three times and analysed by flow cytometry.

As shown in Figure 4, hirudin expressed at the cell surface retains the ability to bind thrombin
25 and glycine linker length did not influence thrombin binding.

To assess the amount of thrombin needed to saturate the hirudin-CD4 expressing cells, two clones were incubated with thrombin up to 82 U/ml. When percentage positive cells was analysed, transfectants were saturated at 41 U/ml thrombin (Figure 4C). According to the mean fluorescence intensities (mfi), however, cells were not saturated even at 82 U/ml (Figure 4D). At

these high experimental thrombin concentrations the background binding to control cells expressing HLA-DR increased significantly.

To elucidate the specificity of thrombin binding to hirudin-CD4 further, blocking experiments were carried out. DAP.3 HLA-hirudin-G3-CD4 transfectants were pre-incubated on ice for 30 minutes with 10µg/ml anti-hirudin mAb or appropriate controls (mouse IgG1 and IgG2a, Dakopatts) for 30 minutes on ice, and washed twice in PBS containing 0.1% BSA before incubating with thrombin for 1 hour at 37°C as above. Thrombin binding was analysed as above.

Pre-incubation with 4158-81-7 inhibited specific thrombin binding to hirudin-CD4 (Figure 5A). Thrombin binding by hirudin-CD4 was demonstrated by incubation with thrombin and comparing labelling with mAb 4107-76-1 (Schlaeppli, 1991) and anti-prothrombin immunoglobulins. 4107-76-1 is directed against the hirudin-thrombin complex and detects neither hirudin without thrombin nor thrombin bound to endogenous thrombin receptors. As shown in Figure 5B, thrombin binding detected with 4107-76-1 paralleled the binding observed with the anti-prothrombin immunoglobulin fraction.

Thus hirudin expressed on the surface of DAP.3 cells retains specific thrombin binding.

Immortalised porcine epithelial cells (IPEC) were transfected with hirudin-CD4 in the same way. As shown in Figure 15A, only the transfected cells bound thrombin, and this was blocked by the 4158-81-7 in a dose-dependent manner (Figure 15B). A human plasma recalcification test system was used for further investigation of the functional effect of expressing surface-tethered hirudin on IPEC. As shown in Figure 15C, untransfected IPEC shortened the clotting time of recalcified plasma to approximately 170 seconds, compared with a control clotting time 370s in the absence of cells. Preincubation with IL-1, which induces TF expression, further reduced the clotting time to below 100s. In contrast, clotting times for transfected IPEC were prolonged, even after preincubation with IL-1-induced TF expression. Incubation with 4158-81-7 reduced the anticoagulant effect in a dose-dependent manner, indicating that the effect was due to the presence of cell-surface hirudin (Figure 15D).

Hirudin expressed on the surface of IPEC thus binds thrombin and also inhibits the clotting of human plasma.

4. Hirudin-CD4-P-selectin expressed by CHO-K1 cells binds thrombin

To investigate whether hirudin-CD4-P-selectin also binds thrombin when expressed at the surface of CHO-K1 cells, these cells were incubated with thrombin for 1 hour at 37°C. After staining with anti-prothrombin immunoglobulins and addition of a second FITC-labelled antibody layer, cells were analysed by flow cytometry.

A distinct binding profile was detected, as shown in Figure 6A. With anti-prothrombin immunoglobulins, background thrombin binding to CHO-K1 cells expressing an irrelevant protein linked to CD4 was detectable after incubation with fairly low concentrations of thrombin. However, specific thrombin binding to hirudin was verified by staining with the specific anti-hirudin/thrombin mAb 4107-76-1 (Figure 6B). With this antibody, background binding by the control CHO-K1 cells was undetectable. It is also evident from Figure 6 that clones expressing hirudin appeared to bind thrombin non-specifically to a different degree, implying that they had different expression levels of endogenous thrombin receptors. This variation in non-specific binding was confirmed with several other clones.

For comparison, results from two CHO-K1 transfectants expressing hirudin-G1-CD4 and hirudin-G2-CD4 (*ie.* no P-selectin sequence) are shown in Figures 6C and 6D. Except for a slightly increased thrombin binding due to better expressed chimeric proteins (higher mfi's), no major differences in binding profiles were detected compared to transfectants expressing hirudin linked to the CD4-P-selectin anchor.

5. Hirudin-CD4-P-selectin is stored in secretory granules and can be released on activation

To examine intracellular accumulation of hirudin and its route from secretory granules to the cell surface, a secretory murine pituitary cell line (D16/16) was transiently transfected with cDNA encoding either hirudin-CD4-P-selectin or hirudin-CD4. This cell line was chosen for two reasons. Firstly, these cells are known to express ACTH in specific storage granules, which are discharged at the cell surface on activation with phorbol esters. Secondly, endothelial cells (which would appear to be the ideal cell type to investigate intracellular targeting of the P-selectin construct) rapidly lose their Weibel-Palade storage granules during *in vitro* culture.

48 hours after transfection, D16/16 cells were stained with antibodies against hirudin and

ACTH. In cells transfected with hirudin-CD4-P-selectin, hirudin was detected in granules evenly distributed in the cytoplasm (Figure 16A). The same pattern of granule distribution was seen with ACTH-specific staining, implying co-localisation with hirudin (Figure 16B). This was verified when both antibodies were used for staining (Figure 16C).

- 5 In contrast, D16/16 cells transfected with hirudin-CD4 did not accumulate hirudin in intracellular granules, but expressed high levels of hirudin at the cell surface (Figure 16D). Dual staining (Figure 16F) revealed only slight co-localisation of hirudin and ACTH.

Cells expressing hirudin-CD4-P-selectin were activated with phorbol ester PMA, and were analysed by flow cytometry. 4158-81-7 did not detect any hirudin at the cell-surface in
10 unstimulated cells (Figure 17A). After 30 minutes of PMA-stimulation, however, hirudin was detected at the cell-surface (Figure 17B). Furthermore, activated D16/16 cells specifically bound to thrombin, unlike non-activated cells (Figure 17C – stained with 4107-76-1).

Thus, by using the granule-containing pituitary cell line D16/16, it was clearly demonstrated that hirudin-CD4-P-selectin can be targeted to specific intracellular storage granules, and that
15 functional chimeric molecules can be released and exposed at the cell surface upon activation.

6. The interaction between thrombin and hirudin-CD4 is abolished when the catalytic site of thrombin is inactivated.

Specific thrombin binding to hirudin-CD4 with and without P-selectin targeting sequence was clear (Figures 4 and 6). To strengthen the specificity of the thrombin-hirudin interaction further,
20 thrombin (210 nmol in 50µl Tris-buffered saline (TBS), 0.1% BSA, pH 7.4) was pre-incubated for 1 hour at 37°C with either:

- native full-length hirudin (Biopharm) at a 10-fold molar excess;
- D-Phe-Pro-Arg chloromethyl ketone dihydrochloride ("PPACK-HCl") (Calbiochem) at 100-fold molar excess; or
- 25 – a synthetic C-terminal hirudin dodecapeptide analog comprising hirudin residues 53-64, with sulfato-Tyr64 (American Diagnostica) at 100-fold molar excess.

The thrombin-dependent catalytic activity was analysed with a small chromogenic oligopeptide substrate (H-D-Phe-Pip-Arg-pNA·2HCl ("S-2238") (Quadrachem).

To ascertain whether thrombin was inactivated by PPACK-HCl and hirudin, 5 µl of each reaction mixture were diluted with 95 ml TBS, 0.1% BSA and incubated with 50 µl 4mM S-2238 for 10 minutes at 37°C.

As expected, no chromogenic conversion was observed with thrombin incubated with PPACK-HCl or hirudin as compared to thrombin incubated without inhibitor, whereas the dodecapeptide did not influence thrombin-dependent catalytic activity as measured by cleavage of S-2238.

The three different preparations were added to transfectants expressing hirudin tethered to the cell surface. Using the procedure described above, thrombin binding was investigated with the anti-prothrombin or anti-hirudin-thrombin antibodies. As can be seen in Figure 7A, thrombin inactivated with hirudin or PPACK-HCl was not bound by hirudin expressed at the cell surface of DAP.3. In addition, only a partial thrombin-dodecapeptide complex binding was observed. In contrast to DAP.3 transfectants, CHO-K1 cells displayed a relatively high thrombin-PPACK-HCl binding (Figure 7B). This interaction was found to be unspecific as illustrated with the anti-hirudin-thrombin mAb 4107-76-1. No specific thrombin-PPACK-HCl-hirudin binding was detected.

This confirms that hirudin tethered to the cell surface specifically and strongly binds thrombin at its catalytic site.

7. Full length and truncated TFPI anchored to CD4 domains is expressed at the cell surface

In order to tether TFPI to the cell membrane, a fusion protein consisting of human CD4₁₆₆₋₄₃₅ linked either to full length TFPI including all three Kunitz domains (TFPI₁₋₂₇₆) or to a truncated form of TFPI lacking Kunitz domain III and the C-terminal (TFPI₁₋₁₈₃) (Wun, 1988) (Figure 8). These were synthesized in a similar way to that described above for hirudin, with the TFPI and CD4 sequences being fused using a cassette cloning strategy, but unlike hirudin, TFPI is a mammalian protein and hence contains an endogenous signal peptide.

DNA encoding the N-terminal portion of TFPI including Kunitz domains I and II (675 bp) was amplified using the primers:

5'-catcgctcgacggatcctagatgatttacacaatgaagaaagtacatgcactttgggc-3'

<SEQ ID 12>

(introducing *SalI* and *BamHI* restriction sites); and

5'-ggacctgcagaattcaaaaaggctgg-3'

<SEQ ID 13>

(containing *EcoRI* and *PstI* sites).

DNA encoding the third Kunitz domain together with the C-terminal end of TFPI (315 bp) was amplified using primers:

5'-agcctttttgaattccacggtcctcat-3'

<SEQ ID 14>

(with an *EcoRI* site); and

5'-cattgctataacaactgcagatattttaac-3'

<SEQ ID 15>

(containing a *PstI* site).

10 CD4₁₆₆₋₄₃₅ was amplified as described above.

By the introduction of restriction sites into the 3' end of the TFPI₁₋₁₈₃ cDNA and the 5' end of the TFPI₁₈₄₋₂₇₆ cDNA, H¹⁸⁴ and G¹⁸⁵ were mutated to C¹⁸⁴ and R¹⁸⁵ in the recombinant fusion proteins (Figure 8). Furthermore, P¹⁸⁶ was mutated to S¹⁸⁶. The stop codon of TFPI was removed by introducing a *PstI* site, thus mutating M²⁷⁶ to I²⁷⁶, and the addition of amino acid C²⁷⁷. In the course of introducing a *PstI* site in the N-terminal end of CD4 domain 3, L¹⁶⁴ and Q¹⁶⁵ were mutated to C¹⁶⁴ and R¹⁶⁵, respectively. In the TFPI₁₈₄₋₂₇₆ cDNA, K²⁶⁵ was found to be mutated to E²⁶⁵ and in CD4₁₆₆₋₄₃₅ V³²⁸ was mutated to A³²⁸ (as described above).

All PCR products were cloned into pBluescript SK(+).

The complete TFPI-CD4 cDNAs were ligated into the *BamHI* site of the pHβActpr-1gpt expression vector.

As above, DAP.3 cells, maintained in supplemented DMEM were transfected with calcium-phosphate as above. Clones were analysed for TFPI and CD4 expression by FACS using murine anti-human TFPI mAbs 4903 or 4904 (American Diagnostica), both at 10 µg/ml, and an undiluted OKT-4 hybridoma supernatant (Reinherz, 1979). 4903 is directed against Kunitz domain I, whereas 4904 is directed against Kunitz domain II. 10⁵ cells for each sample were analysed and, as above, cell line 531 was used as a control.

As shown in Figure 9, both TFPI₁₋₂₇₆-CD4 and TFPI₁₋₁₈₃-CD4 can be expressed at the cell surface.

8. TFPI₁₋₁₈₃-CD4 and TFPI₁₋₂₇₆-CD4 tethered to the cell surface confer FXa binding

To test whether TFPI tethered in this way to the cell surface retains its FXa binding activity, the following binding assay was used.

Stably transfected DAP.3 cells were detached by treatment with PBS, 5 mM EDTA for 10 minutes at 37°C. After 4 washes with excess PBS, 0.1 % BSA (w/v), 2.5x10⁵ cells in 100 µl were incubated for 1 hour at 37°C with increasing concentrations of FXa.

Cells were then washed twice and further incubated for 30 minutes on ice with 10 µg/ml rabbit anti-human FXa immunoglobulins (RAFX-IG, Enzyme Research Laboratories) in 100 µl. After two additional washes, cells were incubated for 30 minutes with FITC-conjugated swine anti-rabbit polyclonal immunoglobulins and analysed by flow cytometry.

As shown in Figure 10, DAP.3 cells expressing TFPI₁₋₂₇₆-CD4 and TFPI₁₋₁₈₃-CD4 at the cell surface strongly bound FXa in a dose-dependent fashion (Figure 10), with significant binding detected at 0.02 nM. No difference in FXa binding was detected between full length and truncated TFPI-CD4.

It was also possible to block FXa binding with a polyclonal anti-TFPI immunoglobulin fraction (4901) or with monoclonals 4903 and 4904.

Cells were incubated on ice for 30 minutes with 4901, 4903, or 4904 at increasing concentrations, using an anti-haemoglobin antiserum (Dakopatts) as a negative control. The cells were then washed twice in PBS, 0.1% BSA, and further incubated with 5 nM FXa for one hour at 37°C. The cells were then washed and incubated with RAFX-IG as above and analysed for FXa binding by FACS.

FXa binding to TFPI₁₋₂₇₆-CD4 decreased 27% and 55% at 10 and 80 µg/ml polyclonal 4901, respectively, compared with cells incubated with the irrelevant anti-haemoglobin polyclonal control (Figure 11A). Diminished FXa binding was also found for TFPI₁₋₁₈₃-CD4 cells pre-incubated with 4901 (Figure 11B).

When TFPI₁₋₂₇₆-CD4 was blocked with either 4903 or 4904, 33% less FXa binding was observed at 40µg/ml mAb, compared with isotype-matched mouse immunoglobulins (Fig. 12). No significant difference in blocking activity was detected between mAbs 4903 and 4904.

This demonstrates for the first time that TFPI retains its FXa binding activity when expressed as

a membrane-bound fusion protein.

9. TFPI₁₋₁₈₃-CD4 and TFPI₁₋₂₇₆-CD4 are both functionally active against FXa

To determine whether TFPI tethered to the cell surface retained its ability to inhibit the function of FXa, the proteolytic activity of FXa was analysed using the chromogenic substrate N-a-Z-D-Arg-Gly-Arg-pNA·2HCl ("S-2765") (Quadrachem).

Transfected DAP.3 cells were detached as described above and washed 4 times with excess TBS, pH 7.4, 0.1% BSA. 0.5×10^6 cells (in 100 μ l) per well were incubated for 1 hour at 37°C with various concentrations of FXa. 50 μ l of 4 mM S-2765 were added and cells were further incubated for 2 hours at 37°C. OD₄₀₅ was measured every 30 seconds and the time required to reach OD₄₀₅=0.1 was determined, showing remaining active FXa.

FXa activity was inhibited by expressed TFPI-CD4 in a dose dependent manner with the greatest inhibition noted when low concentrations of FXa (0.16 nM) were added (Figure 13). In a series of experiments, no significant difference in FXa inhibition was observed between cells expressing TFPI₁₋₁₈₃-CD4 or TFPI₁₋₂₇₆-CD4.

Thus, Kunitz domain II retains its function when tethered to the cell surface in both TFPI₁₋₁₈₃-CD4 and TFPI₁₋₂₇₆-CD4.

10. TF₁₋₂₁₉/FVIIa complex binds irrespectively of the presence of the third Kunitz domain

Binding of tissue factor and factor VIIa can be used to confirm whether Kunitz domain I also retains its function.

Recombinant human TF₁₋₂₁₉ and FVIIa were produced in *E. coli* and CHO-K1, respectively (O'Brien, 1994). These were mixed in equimolar concentrations and incubated at 25°C for 15 minutes to obtain a TF₁₋₂₁₉/FVIIa complex.

Polyclonal rabbit immunoglobulins against human TF were produced according to standard methods.

DAP.3 cells expressing either TFPI₁₋₂₇₆-CD4 or TFPI₁₋₁₈₃-CD4 were incubated with 5 nM FXa for 1 hour at 37°C. Cells were washed twice and TF₁₋₂₁₉/FVIIa complex was added to 2.5×10^5 cells in 100 μ l. After 1 hour at 37°C transfectants were washed twice and incubated with 50 μ l polyclonal rabbit anti-TF immunoglobulins (2.5 μ g/ml) for 30 minutes on ice followed by 2

washes, and further incubation with FITC-conjugated swine anti-rabbit immunoglobulins. Positive cells were analysed by flow cytometry.

TF₁₋₂₁₉/FVIIa bound equally efficient to both TFPI₁₋₂₇₆-CD4 (Fig. 14A) and TFPI₁₋₁₈₃-CD4 (Fig. 14B), while no binding at all was detected to control cell line 531.

- 5 To confirm specific binding to Kunitz domain I by the TF₁₋₂₁₉/FVIIa complex, FVIIa was inactivated by pre-incubation with 1,5-dansyl-Glu-Gly-Arg-chloromethyl ketone, dihydrochloride ("1,5-DNS-GGACK·HCl"). This binds to the active site of FVIIa and inhibits binding to TFPI whilst not affecting the formation of the TF₁₋₂₁₉/FVIIa complex (Bajaj, 1992).

- 10 FVIIa was first incubated with a 100-fold molar excess of 1,5-DNS-GGACK·HCl for 18 hours at 20°C and repurified by ion-exchange chromatography. Active-site inhibited FVIIa (FVIIai) was incubated with an equimolar concentration of TF₁₋₂₁₉ at 25°C for 15 minutes and then added to 2.5x10⁵ cells in 100 µl. Subsequent steps were as described above.

- As can be seen from figure 14, significantly less TF₁₋₂₁₉/FVIIai complex bound to TFPI-CD4 expressing cells as compared to bound "active" TF₁₋₂₁₉/FVIIa. No difference was observed
15 between DAP.3 transfected with TFPI₁₋₂₇₆-CD4 or TFPI₁₋₁₈₃-CD4.

Thus Kunitz domain I also retains its function when tethered to the cell surface in TFPI₁₋₁₈₃-CD4 and TFPI₁₋₂₇₆-CD4. It is therefore apparent that TFPI tethered at the cell surface is functionally active as a whole.

11. TFPI-CD4 expressed on IPEC binds relevant human clotting factors and porcine TF

- 20 As shown in Figure 18, the TFPI-CD4 fusion protein can be expressed on IPEC and retains the ability to bind FXa and FVIIa. To demonstrate that TFPI can physically interact with porcine TF, a competitive inhibition approach using soluble human TF was adopted. As shown in Figure 19A, in the presence of saturating concentrations of FXa and FVIIa, the binding of soluble human TF to TFPI-transfected IPEC (pre-treated with IL-1α) was significantly reduced
25 compared to the binding by TF-negative control transfectants (not IL-1α activated). This suggests that porcine TF was competing with soluble human TF for VIIa, and therefore for TFPI binding. Figure 19B supports this, showing that binding of soluble human TF to TFPI-CD4-transfected IPEC (IL-1α pre-activated) was increased if the transfectants were incubated with increasing concentrations of antibody against porcine TF. The effect of this
30 antibody could reflect inhibition of the interaction between porcine TF and FVIIa, or between

porcine TF-VIIa complexes and TFPI-CD4. Either way, the results suggest that the TFPI-CD4-fusion protein expressed on the surface of IPEC physically interacts with porcine TF-FVIIa.

12. TFPI-CD4 expressed on IPEC inhibits TF-dependent fibrin generation

5 Figure 20A shows the results of a single representative experiment to illustrate the procoagulant phenotype of TFPI-CD4-transfected IPEC. The presence of the fusion protein on transfected cells consistently prolonged clotting times when compared with control IPEC. This effect was only observed, however, after IL-1 α activation – TFPI-CD4 expression had no influence on clotting times when TF-negative IPEC were used. Thus, the TFPI-CD4, as
10 expected, inhibited TF-dependent, but not TF-independent fibrin generation. An anti-TFPI antibody, used in increasing concentrations during a pre-incubation step, was able to normalise clotting times back to those seen with untransfected IL-1 α -activated control IPEC (Figure 20B), indicating that the prolongation of clotting times in the presence of the transfected cells was due entirely to the specific inhibitory action of TFPI.

15 13. Expression of a protein C activator at the cell membrane

To express heterologous constructs comprising the protein C activator isolated from the venom of *Agkistrodon contortrix contortrix* (McMullen, 1989; Kisiel, 1987), a cDNA encoding the protein was synthesised. The protein sequence is <SEQ ID 16>:

20 V I G G D E C N I N E H R F L A L V Y A N G S L C G
G T L I N Q E W V L T A R H C D R G N M R I Y L G M
H N L K V L N K D A L R R F P K E K Y F C L N T R N
D T I W D K D I M L I R L N R P V R N S A H I A P L
S L P S N P P S V G S V C R I M G W G T I T S P N A
T L P D V P H C A N I N I L D Y A V C Q A A Y K G L
25 A A T T L C A G I L E G G K D T C K G D S G G P L I
C N G Q F Q G I L S V G G N P C A Q P R K P G I Y T
K V F D Y T D W I Q S I I S G N T D A T C P P

In accordance with porcine codon-usage bias (which is applicable to most, if not all, mammalian
30 cells), the following single stranded DNA was synthesised <SEQ ID 17>:

GTG ATC GGC GGC GAC GAG TGC AAC ATC AAC GAG CAC CGC
TTC CTG GCC CTG GTG TAC GCC AAC GGC AGC CTG TGC GGC
GGC ACC CTG ATC AAC CAG GAG TGG GTG CTG ACC GCC CGC
CAC TGC GAC CGC GGC AAC ATG CGC ATC TAC CTG GGC ATG

5 CAC AAC CTG AAG GTG CTG AAC AAG GAC GCC CTG CGC CGC
 TTC CCC AAG GAG AAG TAC TTC TGC CTG AAC ACC CGC AAC
 GAC ACC ATC TGG GAC AAG GAC ATC ATG CTG ATC CGC CTG
 AAC CGC CCC GTG CGC AAC AGC GCC CAC ATC GCC CCC CTG
 AGC CTG CCC AGC AAC CCC CCC AGC GTG GGC AGC GTG TGC
 CGC ATC ATG GGC TGG GGC ACC ATC ACC AGC CCC AAC GCC
 ACC CTG CCC GAC GTG CCC CAC TGC GCC AAC ATC AAC ATC
 CTG GAC TAC GCC GTG TGC CAG GCC GCC TAC AAG GGC CTG
 10 GCC GCC ACC ACC CTG TGC GCC GGC ATC CTG GAG GGC GGC
 AAG GAC ACC TGC AAG GGC GAC AGC GGC GGC CCC CTG ATC
 TGC AAC GGC CAG TTC CAG GGC ATC CTG AGC GTG GGC GGC
 AAC CCC TGC GCC CAG CCC CGC AAG CCC GGC ATC TAC ACC
 AAG GTG TTC GAC TAC ACC GAC TGG ATC CAG AGC ATC ATC
 15 AGC GGC AAC ACC GAC GCC ACC TGC CCC CCC

This single-stranded DNA was annealed to complementary oligonucleotides to give a double-stranded molecule. Restriction sites are included at either end of the double-stranded DNA, to which is ligated a CD4 anchor and a P-selectin signal sequence in a similar way to that described above. The resulting molecule was ligated, as before, into the pH β Actpr-1gpt vector.

20 As an alternative DNA source, a snake cDNA library could be screened on the basis of the known protein sequence.

14. Co-expression of TFPI-CD4 and hirudin-CD5 causes inhibition of TF-dependent and TF-independent clotting

Stable transfectants expressing both TFPI-CD4 and hirudin-CD4 were generated. As shown in
 25 Figure 21A, the primary transfectants expressed variable levels of hirudin and low levels of TFPI. Despite this modest expression by the majority of transfectants, however, the procoagulant phenotype of these cells was significantly reduced compared to controls (Figure 21B). The cell-surface presence of both anticoagulant molecules on IL-1 α -activated IPEC markedly prolonged the time to clot plasma to approximately 300 seconds, which is
 30 approaching the time taken for recalcified human plasma to clot spontaneously. Blocking studies with anti-hirudin and anti-TFPI antibodies confirmed that the altered phenotype of these double transfectants was due to specific inhibition of coagulation by the expressed hirudin and TFPI.

It will be understood that the invention is described above by way of example only and
 35 modifications may be made whilst remaining within the scope and spirit of the invention.

REFERENCES (THE CONTENTS OF WHICH ARE INCORPORATED HEREIN)

- Bach FH, Winkler H, Ferran C, Hancock WW, Robson SC. Delayed xenograft rejection. *Immunology Today* 1996; 17(8); 379-384.
- Bajaj SP, Sabharwal AK, Gorka J, Birktoft JJ. Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca^{2+} -binding site in the protease domain. *PNAS USA* 1992; 89: 152-156.
- Bradley A, Liu P. Target practice in transgenics. *Nature Genet.* 1996; 14: 121-123.
- Clarke AR. The adenovirus and the egg: a new approach to transgenesis. *Nature Biotech.* 1996; 14: 942.
- 10 Dang QD, Guinto ER, Di Cera E. Rational engineering of activity and specificity in a serine protease. *Nature Biotech.* 1997; 15: 146-149.
- Diamond LE, McCurry KR, Oldham ER, Tone M, Waldmann H, Platt JL, Logan JS. Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement. *Transplant Immunol.* 1995; 3: 305-312.
- 15 Disdier M, Morrissey JH, Fugate RD, Bainton DF, McEver RP. Cytoplasmic domain of P-selectin (CD62) contains the signal for sorting into the regulated secretory pathway. *Molec. Biol. Cell.* 1992; 3: 309-321.
- Dodt J, Kohler S, Baici A. Interaction of site specific hirudin variants with alpha-thrombin. *FEBS Lett.* 1988; 229: 87-90
- 20 Green SA, Setiadi H, McEver RP, Kelly RB. The cytoplasmic domain of P-selectin contains a sorting determinant that mediates rapid degradation in lysosomes. *J. Cell. Biol.* 1994; 124: 435-448.
- Gunning P, Leavitt J, Muscat G, Ng SY, Kedes L. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. *PNAS USA.* 1987; 84: 4831-5
- 25 Hamamoto T, Yamamoto M, Nordfang O, Petersen JGL, Foster DC, Kisiel W. Inhibitory properties of full-length and truncated recombinant TFPI variants expressed in *Saccharomyces cerevisiae*. *J. Biol. Chem.* 1993; 268: 13344-13351.
- Heckl-Östreicher B, Binder R, Kirschfink M. Functional activity of the membrane-associated complement inhibitor CD59 in a pig-to-human *in vitro* model for hyperacute xenograft

rejection. *Clin. Exp. Immunol.* 1995;102:589-595.

Holmes N, Ennis P, Wan AM, Denney DW, Parham P. Multiple genetic mechanisms have contributed to the generation of the HLA-A2/A28 family of class I MHC molecules. *J Immunol.* 1987; 139: 936-41

- 5 Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. *Cell.* 1989; 56: 1033-44

- Kiely J-M, Cybulsky MI, Luscinskas FW, Gimborne MA. Immunoselective targeting of an anti-thrombin agent to the surface of cytokine-activated vascular endothelial cells. *Arterioscler. Thromb. Vasc. Biol.* 1995; 15: 1211-1218.

Kisiel E, Kondo S, Smith KJ, McMullen BA, Smith LF. Characterization of a protein C activator from *Agkistrodon contortrix contortrix* venom. *J.Biol.Chem.* 1987;262:12607-13.

Knapp A, Degenhardt T, Dodt J. Hirudisins. *J. Biol. Chem.* 1992; 34: 24230-24234.

- 15 Langford GA, Cozzi E, Yannoutsos N, Lancaster R, Elsome K, Chen P, White DGJ. Production of pigs transgenic for human regulators of complement activation using YAC technology. *Transplant Proc.* 1996; 28: 862-863.

Lechler RI, Bal V, Rothbard JB, Germain RN, Sekaly R, Long EO, Lamb J. Structural and functional studies of HLA-DR restricted antigen recognition by human helper T lymphocyte clones by using transfected murine cell lines. *J. Immunol.* 1988; 141: 3003-3009.

- 20 McCurry KR, Diamond LE, Kooyman DL, Byrne GW, Martin MJ, Logan JS, Platt JL. Human complement regulatory proteins expressed in transgenic swine protect swine xenografts from humoral injury. *Transplant Proc.* 1996; 28: 758.

McMullen BA, Fujikawa K, Kisiel W. Primary structure of a protein C activator from *Agkistrodon contortrix contortrix* venom. *Biochemistry* 1989; 28: 674-679.

- 25 Maddon PJ, Littman DR, Godfrey M, Maddon DE, Chess L, Axel R. The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. *Cell.* 1985; 42: 93-104

Mao SS, Huang J, Welebob C, Neeper MP, Garsky VM, Shafer JA. Identification and characterization of variants of tick anticoagulant peptide with increased inhibitory potency

toward human factor Xa. *Biochemistry* 1995; 34: 5098-5103.

Merkenschlager M, Altmann DM, Ikeda H. T cell alloresponses against HLA-DQ and -DR products involve multiple epitopes on the CD4 molecule. Distinct mechanisms contribute to the inhibition of HLA class II-dependent and -independent T cell responses by antibodies to CD4.

5 *J.Immunol.* 1990;145: 3181-7.

O'Brien DP, Kemball-Cook G, Hutchinson AM, Martin DM, Johnson DJ, Byfield PG, Takamiya O, Tuddenham EG, McVey JH. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. *Biochemistry* 1994; 33:14162-9.

10 Reinherz EL, Kung PC, Goldstein G, Schlossman SF. Separation of functional subsets of human T cells by a monoclonal antibody. *PNAS USA.* 1979; 76: 4061-4065

Schlaeppli JM. Preparation of monoclonal antibodies to the thrombin/hirudin complex. *Thromb Res.* 1991; 62: 459-470

Skern T, Bischoff R, Jallat S, Dott K, Ali-Hadji D, Clesse D, Kieny MP, Courtney M. Sulphation of hirudin in BHK cells. *FEBS.* 1990; 1: 36-38.

15 Squinto SP. Xenogeneic organ transplantation. *Curr. Opin. Biotech.* 1996; 7: 641-645.

Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. *Thrombosis & Haemostasis.* 1993; 70: 105-110.

Wheeler MB. Development and validation of swine embryonic stem cells: a review. *Reprod. Fertil. Dec.* 1994; 6:563-568.

20 White D, Cozzi E, Langford G, Oglesby T, Wang M, Wright L, Wallwork J. The control of hyperacute rejection by genetic engineering of the donor species. *Eye* 1995; 9: 185-189.

Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. *J. Biol. Chem.* 1988; 263: 6001-4

25 Yannoutsos N, Langford GA, Cozzi E, Lancaster R, Elsome K, Chen P, White DJG. Production of pigs transgenic for human regulators of complement activation. *Transplant Proc.* 1995; 27: 324-325.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: RPMS Technology Limited
(B) STREET: Commonwealth Building
(C) CITY: Du Cane Road
(D) STATE: London
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP): W12 0NN

(ii) TITLE OF INVENTION: Coagulation inhibition

(iii) NUMBER OF SEQUENCES: 17

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk 720K
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Ver 2.0/Microsoft Word 97

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/GB98/

(2) INFORMATION FOR SEQ ID NO: 1

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 1

cagtgtcgac ggatccatgg ccgtcatggc gccccga

37

(2) INFORMATION FOR SEQ ID NO: 2

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 2

gtcagtgttaa acaaccgccc aggtctgggt cagg

34

(2) INFORMATION FOR SEQ ID NO: 3

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 3

accagacct gggcggttgt ttacactgac tgcacc

36

5 (2) INFORMATION FOR SEQ ID NO: 4

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10

- (ii) MOLECULE TYPE: DNA

15 (xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 4

gacgctgcag aattcttgca ggtattcttc cgggatt

37

20 (2) INFORMATION FOR SEQ ID NO: 5

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25

- (ii) MOLECULE TYPE: DNA

30 (xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 5

aattaggagg ttctggaggc tgca

24

35 (2) INFORMATION FOR SEQ ID NO: 6

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40

- (ii) MOLECULE TYPE: DNA

45 (xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 6

gcctccagaa ctcct

16

50 (2) INFORMATION FOR SEQ ID NO: 7

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

55

- (ii) MOLECULE TYPE: DNA

60 (xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 7

tgtctgcagg aaccagaaga aggtggaatt ca

32

65 (2) INFORMATION FOR SEQ ID NO: 8

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 nucleotides
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 8

gtgggatccg cctggcctcg tgcctcaa 28

(2) INFORMATION FOR SEQ ID NO: 9

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 53 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 9

gtctgaaacg ctttctgaag aagatgccta gcccaatgaa aagcaggagg ccg 53

(2) INFORMATION FOR SEQ ID NO: 10

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 10

tgggctaggc atcttcttca gaaagcgttt cagacaaaaa ga 42

(2) INFORMATION FOR SEQ ID NO: 11

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 11

gaccaggatc cggacaggtc tctta 25

(2) INFORMATION FOR SEQ ID NO: 12

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 12

catcgctgac ggatcctaga tgatttacac aatgaagaaa gtacatgcac tttgggc 57

(2) INFORMATION FOR SEQ ID NO: 13

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 nucleotides
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 13

ggacctgcag aattcaaaaa ggctgg 26

(2) INFORMATION FOR SEQ ID NO: 14

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 28 nucleotides
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 14

agcctttttg aattccacgg tccctcat 28

(2) INFORMATION FOR SEQ ID NO: 15

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 31 nucleotides
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 15

cattgctata acaactgcag atatttttaa c 31

(2) INFORMATION FOR SEQ ID NO: 16

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 231 amino acids
 (B) TYPE: protein
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Agkistrodon contortrix contortrix*

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 16

Val Ile Gly Gly Asp Glu Cys Asn Ile Asn Glu His Arg Phe Leu Ala
 1 5 10 15

Leu Val Tyr Ala Asn Gly Ser Leu Cys Gly Gly Thr Leu Ile Asn Gln
 20 25 30

Glu Trp Val Leu Thr Ala Arg His Cys Asp Arg Gly Asn Met Arg Ile
 35 40 45

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 693 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION FOR SEQ ID NO: 17


gtgatcggcg	ggcacgagtg	caacatcaac	gagcacgcgt	tcctggccct	ggtgtacgcc	60
aacggcagcc	tgtgcggcgg	cacctgatc	aaccaggagt	gggtgctgac	cgcccgccac	120
tgcgaccg	gcaacatgcg	catctacctg	ggcatgcaca	acctgaaggt	gctgaacaag	180
gacgcctgc	gccgcttccc	caaggagaag	tacttctgcc	tgaacacccg	caacgacacc	240
atctgggaca	aggacatcat	gctgatccgc	ctgaaccgcc	ccgtgcgcaa	cagcgcccac	300
atcgccccc	tgagcctgcc	cagcaacccc	cccagcgtgg	gcagcgtgtg	ccgcatcatg	360
ggctggggca	ccatcaccag	cccacacgcc	accctgcccg	acgtgcccc	ctgcgccaac	420
atcaacatcc	tggactacgc	cgtgtgccag	gccgcctaca	agggcctggc	cgccaccacc	480
ctgtgcgcgc	gcacccagta	ggcgggcaag	gacacctgca	agggcgacag	cggcggcccc	540
ctgatctgca	acggccagtt	ccagggcac	ctgagcgtgg	gcggcaaccc	ctgcgcccag	600
ccccctaagc	ccggcatcta	caccaagggt	ttcgactaca	ccgaactgat	ccagagcatc	660
atcagcgqca	acaccgacgc	cacctgcccc	ccc			693

CLAIMS


1. A protein comprising a region with anticoagulant activity and a region which can anchor said protein to a cell membrane.
2. A protein according to claim 1 further comprising a targeting sequence which prevents the protein from being constitutively expressed at the cell surface.
3. A protein according to claim 1 or claim 2, wherein the anticoagulant region comprises the sequence of a hirudin, a tissue factor pathway inhibitor, a tick anticoagulant peptide, or a protein C activator.
4. A protein according to claim 1 or claim 2, wherein the anchor region is a sequence capable of attaching the protein to a lipid bilayer.
5. A protein according to claim 4, wherein the anchor region comprises the transmembrane sequence from a membrane protein.
6. A protein according to claim 2, wherein said targeting sequence is a sequence which can target a nascent polypeptide to a secretory granule.
7. A protein according to claim 6 wherein said secretory granule does not fuse with the cell's plasma membrane until the cell is suitably stimulated.
8. A protein according to claim 7, wherein said secretory granule is a Weibel-Palade body.
9. A protein according to claim 6 wherein said targeting sequence is the cytoplasmic domain of P-selectin.
10. A protein according to any one of the previous claims wherein said anchor sequence is that of P-selectin.
11. A polynucleotide encoding a protein according to any one of the previous claims.

12. A vector comprising a polynucleotide according to claim 11.
13. A delivery system comprising a protein according to any one of claims 1 to 10, a polynucleotide according to claim 11, or a vector according to claim 12.
14. A method of transfecting a cell with a vector according to claim 12.
- 5 15. A cell transfected according to claim 14.
16. Biological tissue comprising a cell according to claim 15.
17. An animal comprising biological tissue according to claim 16 and/or cell according to claim 15.
18. An animal according to claim 17, wherein said animal is a transgenic pig or sheep.
- 10 19. A method of rendering a tissue or organ suitable for transplantation, comprising expressing a protein according to any one of claims 1 to 10 on the surface of endothelial cells in said tissue or organ.
20. A method of transplantation comprising transplanting biological tissue according to claim 16 from a donor animal into a recipient animal.


A



B



C



D




FIG. 1








FIG. 2




4 / 26

A


- ▲ HLA-hirudin-G1-CD4
- ◆ HLA-hirudin-G1-CD4
- HLA-hirudin-G1-CD4
- HLA-DR control

B**FIG. 4****C**

- ◆ HLA-hirudin-G2-CD4
- HLA-hirudin-G3-CD4
- ▲ untransfected cells
- HLA-DR control

D

5 / 26



FIG. 5

6 / 26



FIG. 6Labelling antibody

anti-prothrombin

anti-hirudin/ thrombin complex

A**B**


- = HLA-hirudin-G1-CD4-P-selectin
- = HLA-hirudin-G2-CD4-P-selectin
- ▲ = control

C**D**

- ◆ = HLA-hirudin-G1-CD4
- = HLA-hirudin-G2-CD4
- ▲ = control

FIG. 7 **CHO-K1**

A **DAP.3** **B**






FIG. 8

9 / 26







FIG. 9

10 / 26


FIG. 10▲ = TFPI₁₋₂₇₆-CD4○ & ■ = TFPI₁₋₁₈₃-CD4

▽ = control

11 / 26

FIG. 11
B**A**

12 / 26


FIG.12

□ = mAb 4903

▲ = mAb 4904

● = control

13/26

FIG. 13








FIG. 14

15 / 26

FIG. 15A**FIG. 15B**

16/26

FIG. 15C**FIG. 15D**

17 / 26

FIG. 16A




FIG. 16B





FIG. 16C



18 / 26

FIG. 16D



FIG. 16E





FIG. 16F



19/26



20 / 26

FIG. 17B




FIG. 17C






FIG. 18A



23 / 26

FIG. 18B



24 / 26

FIG. 19A





FIG. 19B



25 / 26

FIG. 20A







FIG. 20B



26 / 26

FIG. 21A**FIG. 21B**

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00850

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/62 A01K67/027 C12N15/00 C07K14/705 C07K14/815
C07K14/81 C12N9/64

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A01K C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 109 113 A (CARAS INGRID W ET AL) 28 April 1992	1,4,5, 11-16
Y	see the whole document	1-10, 17-20

X	WO 96 04378 A (CHIRON CORP) 15 February 1996	1,3, 11-16
Y	see claims 1-6,10-20,24,25,34,37,40; tables 73,79	1-10,19, 20

Y	DORLING, A. ET AL.: "Clinical xenotransplantation of solid organs" LANCET THE., vol. 349, no. 9055, 22 March 1997, pages 867-871, XP002074455 LONDON GB see page 868, column 2, paragraph 2 - paragraph 4; figure 2	3,17-20

	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search

18 August 1998

Date of mailing of the international search report

28/08/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00850

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BACH, F.H. ET AL.: "Delayed xenograft rejection" IMMUNOLOGY TODAY, vol. 96, no. 17, August 1996, pages 379-384, XP002074456 CAMBRIDGE GB cited in the application see the whole document ----	3,17-20
Y	LANTIERI, L.A. ET AL.: "Prevention of microvascular thrombosis by topical application of recombinant Tissue Factor Pathway Inhibitor" PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 97, no. 3, March 1996, pages 587-594, XP002074457 see the whole document ----	3,17-20
Y	WO 96 04377 A (CHIRON CORP) 15 February 1996 see the whole document ----	3,17-20
X	US 5 223 408 A (GOEDEL DAVID V ET AL) 29 June 1993 see the whole document ----	1,5,11, 12,14
Y	DISDIER, M. ET AL.: "Cytoplasmic domain of P-selectin (CD62) contains the signal for sorting into the regulated secretory pathway" MOLECULAR BIOLOGY OF THE CELL, vol. 3, 1992, pages 309-321, XP002074458 cited in the application see the whole document ----	2,6-10
Y	GREEN, S.A. ET AL.: "The cytoplasmic domain of P-selectin contains a sorting determinant that mediates rapid degradation in lysosomes" JOURNAL OF CELLULAR BIOSCHEMISTRY, vol. 124, 1994, pages 435-448, XP002074459 cited in the application see page 442, column 2, paragraph 4 ----	2,6-10
Y	WO 94 20537 A (NOVONORDISK AS ;NORDFANG OLE (DK); PETERSEN JENS G LITSKE (DK); BJ) 15 September 1994 see the whole document ----	3

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00850

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SELINKA, H.C. ET AL.: "A chimeric Poliovirus/CD4 receptor confers susceptibility to Poliovirus on mouse cells"</p> <p>JOURNAL OF VIROLOGY., vol. 66, no. 4, April 1992, pages 2523-526, XP002074460</p> <p>ICAN SOCIETY FOR MICROBIOLOGY US see the whole document</p> <p style="text-align: center;">----</p>	1
P,X	<p>RIESBECK, K. ET AL.: "Human Tissue Factor Pathway Inhibitor fused to CD4 binds both FXa and TF-FVIIa at the cell surface"</p> <p>THROMBOSIS AND HAEMOSTASIS, vol. 78, no. 6, December 1997, pages 1488-1494, XP002074461</p> <p>see the whole document</p> <p style="text-align: center;">-----</p>	1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 98/ 00850

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 20
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00850

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5109113 A	28-04-1992	AU 629517 B	08-10-1992
		AU 2308788 A	01-03-1989
		DE 3854328 D	21-09-1995
		DE 3854328 T	28-03-1996
		EP 0371999 A	13-06-1990
		JP 2504467 T	20-12-1990
		US 5374548 A	20-12-1994
		WO 8901041 A	09-02-1989
		US 5763224 A	09-06-1998
		US 5264357 A	23-11-1993
		AU 612572 B	18-07-1991
		AU 7242687 A	19-11-1987
		DE 3750379 D	22-09-1994
		DE 3750379 T	23-02-1995
		EP 0244267 A	04-11-1987
		JP 2713875 B	16-02-1998
		JP 8242882 A	24-09-1996
		JP 2686257 B	08-12-1997
		JP 63102699 A	07-05-1988
WO 9604378 A	15-02-1996	US 5589359 A	31-12-1996
		AU 3150095 A	04-03-1996
		CA 2196290 A	15-02-1996
		EP 0776366 A	04-06-1997
		JP 10503375 T	31-03-1998
		US 5696088 A	09-12-1997
		US 5563123 A	08-10-1996
WO 9604377 A	15-02-1996	AU 3104495 A	04-03-1996
		CA 2196296 A	15-02-1996
		EP 0774001 A	21-05-1997
		JP 10507071 T	14-07-1998
US 5223408 A	29-06-1993	US 5736135 A	07-04-1998
WO 9420537 A	15-09-1994	AU 6202294 A	26-09-1994
		ZA 9401414 A	28-09-1994